SEK 0.65
(-3.25%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -13.69 Million SEK | 7.42% |
2022 | -14.78 Million SEK | -30.63% |
2021 | -11.32 Million SEK | -45.79% |
2020 | -7.76 Million SEK | 7.21% |
2019 | -8.36 Million SEK | -34.56% |
2018 | -6.21 Million SEK | -33.44% |
2017 | -4.66 Million SEK | -139.54% |
2016 | -1.94 Million SEK | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -3.61 Million SEK | 16.19% |
2024 Q2 | -3.8 Million SEK | -5.26% |
2023 Q4 | -4.31 Million SEK | -37.69% |
2023 Q3 | -3.13 Million SEK | -11.03% |
2023 FY | -13.69 Million SEK | 7.42% |
2023 Q2 | -2.82 Million SEK | 17.76% |
2023 Q1 | -3.42 Million SEK | 10.47% |
2022 Q1 | -3.66 Million SEK | -20.15% |
2022 FY | -14.78 Million SEK | -30.63% |
2022 Q3 | -3.81 Million SEK | -9.78% |
2022 Q2 | -3.47 Million SEK | 5.21% |
2022 Q4 | -3.83 Million SEK | -0.37% |
2021 Q3 | -2.95 Million SEK | 0.0% |
2021 FY | -11.32 Million SEK | -45.79% |
2021 Q4 | -3.05 Million SEK | -3.18% |
2020 FY | -7.76 Million SEK | 7.21% |
2019 FY | -8.36 Million SEK | -34.56% |
2018 FY | -6.21 Million SEK | -33.44% |
2017 FY | -4.66 Million SEK | -139.54% |
2016 FY | -1.94 Million SEK | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
AlzeCure Pharma AB (publ) | -37.16 Million SEK | 63.164% |
BioGaia AB (publ) | 365.35 Million SEK | 103.747% |
Enzymatica AB (publ) | -49.72 Million SEK | 72.468% |
Enorama Pharma AB (publ) | -44.61 Million SEK | 69.312% |
Gabather AB (publ) | -9.43 Million SEK | -45.078% |
Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 61.74% |
Moberg Pharma AB (publ) | -21.09 Million SEK | 35.092% |
Nanexa AB (publ) | -76.39 Million SEK | 82.079% |
Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 11.126% |
ODI Pharma AB | 355.97 Thousand SEK | 3946.1% |
Orexo AB (publ) | -128.3 Million SEK | 89.329% |
Probi AB (publ) | 16.81 Million SEK | 181.402% |
Swedencare AB (publ) | 58.6 Million SEK | 123.363% |
Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 100.568% |
Toleranzia AB | -7.45 Million SEK | -83.55% |
Vivesto AB | -367.03 Million SEK | 96.27% |